Medication info
Liraglutide Duo Extended-Release Tablet 2.5/1000 mg (Linagliptin, Metformin)

Liraglutide Duo Extended-Release Tablet 2.5/1000 mg (Linagliptin, Metformin)

Prescription medicationTabletOral
Ingredient · strength
Linagliptin Besylate›3.34mg / 1 tabletMetformin Hydrochloride›1000mg / 1 tablet
Manufacturer / importer
Kyungbo Pharmaceutical Co., Ltd.
Appearance
This medication is a bright yellow, oval-shaped extended-release film-coated tablet.
Packaging
30 tablets/bottle, 60 tablets/bottle
Approval status
Active

MFDS item code 202401557 · Approved 2024.06.27 · Insurance code 665003360

Summary

Main use
Improvement of glycemic control in patients with type 2 diabetes mellitus
Who takes it
Adults
Adult dose
For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg (linagliptin besylate 6.67mg) and extended-release metformin hydrochloride 2000 mg. This medicine should be taken once daily with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 5/1000 mg extended-release tablet once daily. Patients taking this medicine as 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine equivalent to the patient's current metformin hydrochloride dose, together with a total daily dose of linagliptin 5mg, should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or higher and less than 60mL/min or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or higher and less than 60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Ingredients

Manufacturer
Kyungbo Pharmaceutical Co., Ltd.

Efficacy & effects

Improvement of glycemic control in patients with type 2 diabetes mellitus

View approved original text

This medication helps control blood sugar levels in patients with type 2 diabetes by using linagliptin and metformin together. It supports dietary and exercise therapy to effectively manage blood sugar. This enables patients to maintain stable blood sugar levels and helps prevent complications. It provides a safe and reliable treatment to improve blood sugar control.

How to take

Adult dose

For antidiabetic therapy, the dose of this medicine should be determined based on each patient's current treatment regimen, efficacy, and tolerability, without exceeding the maximum recommended daily doses of each component: linagliptin 5mg (linagliptin besylate 6.67mg) and extended-release metformin hydrochloride 2000 mg. This medicine should be taken once daily with the evening meal. To reduce gastrointestinal adverse reactions associated with metformin use, the dose of metformin hydrochloride should be increased gradually. To maintain its extended-release properties, swallow this medicine whole; do not split, crush, grind, or chew it. Take one 5/1000 mg extended-release tablet once daily. Patients taking this medicine as 2.5/1000 mg extended-release tablets should take 2 tablets together once daily. 1. Patients not currently treated with metformin: The initial total daily dose of this medicine is linagliptin 5 mg and metformin hydrochloride 1000mg. The dose of metformin hydrochloride may be increased gradually up to the maximum recommended daily dose of 2000 mg. 2. Patients receiving treatment with metformin - For patients who cannot achieve adequate glycemic control with metformin monotherapy, the initial dose of this medicine is a total daily dose of linagliptin 5 mg and the patient's current dose of metformin hydrochloride. - For patients who cannot achieve adequate glycemic control with metformin plus a sulfonylurea or metformin plus insulin, an initial dose of this medicine equivalent to the patient's current metformin hydrochloride dose, together with a total daily dose of linagliptin 5mg, should be considered. When this medicine is coadministered with insulin or a sulfonylurea, a reduction in the insulin or sulfonylurea dose may be necessary to reduce the risk of hypoglycemia. - When switching from an immediate-release metformin formulation to an extended-release formulation, glycemic control should be closely monitored and dosage adjustments made as appropriate if necessary. - When switching from combination therapy with linagliptin and extended-release metformin to this medicine, the dose of this medicine is the patient's current dose of linagliptin and extended-release metformin hydrochloride. Renal impairment Because dosage adjustment according to renal function is required, assessment of renal function is recommended before treatment with this medicine and periodically thereafter. No dose adjustment is necessary in patients with mild renal impairment [creatinine clearance (CrCl) ≧ 60mL/min or estimated glomerular filtration rate (eGFR) ≧ 60mL/min/1.73 m2]. In patients with moderate renal impairment (CKD stage 3A), with creatinine clearance (CrCl) of 45mL/min or higher and less than 60mL/min or estimated glomerular filtration rate (eGFR) of 45mL/min/1.73m2 or higher and less than 60mL/min/1.73m2, this medicine may be used with adjustment of the metformin hydrochloride dose as follows, provided it is well tolerated and the patient has no other condition that may increase the risk of lactic acidosis. The starting dose of metformin hydrochloride is 500mg or 750mg once daily; therefore, treatment should not be initiated with this medicine. The maximum daily dose of metformin hydrochloride is 1000mg. If creatinine clearance (CrCl) decreases to less than 45mL/min or estimated glomerular filtration rate (eGFR) decreases to less than 45mL/min/1.73m2, this medicine should be discontinued immediately.

Precautions

This drug can rarely cause a serious condition called lactic acidosis, so it should be avoided in patients with impaired kidney function or in situations where there is a risk of rapid deterioration of kidney function due to acute infection, dehydration, or severe trauma. It should not be administered to patients who are allergic to any of the ingredients, or those with type 1 diabetes, diabetic ketoacidosis, or severe liver dysfunction. There is a risk of hypoglycemia, so blood sugar levels should be closely monitored, especially when used with insulin or sulfonylureas. Elderly patients with reduced kidney function or those taking medications that may affect kidney function should undergo regular kidney function tests, and dosage adjustments may be necessary. Acute pancreatitis or skin blistering diseases may occur, so if any abnormal symptoms arise while taking this medication, a doctor should be consulted immediately. It is advised to take this medication with meals or after meals to reduce gastrointestinal discomfort, and the tablets should not be chewed or crushed, but swallowed whole. Women who are pregnant or breastfeeding should avoid using this medication and should consult with a doctor if planning to become pregnant or if they are already pregnant. There may be drug interactions, so it is essential to inform the doctor or pharmacist of any other medications being taken. If using iodinated contrast agents during radiological examinations, it is necessary to discontinue this medication for a certain period before and after the examination and to check kidney function. Excessive alcohol consumption should be avoided during treatment, and this medication should not be used in acute alcohol intoxication. Overdose may lead to gastrointestinal disturbances or lactic acidosis; if suspected, immediate medical attention should be sought. This medication should be kept out of reach of children and stored away from moisture and direct sunlight.

Side effects

  • severe lactic acidosis
  • hypoglycemia
  • nasopharyngitis
  • hypersensitivity reaction
  • angioedema
  • urticaria
  • lactic acidosis
  • abnormal vitamin B12 absorption test
  • hypoglycemic episode
  • taste disorder
Show 134 more
  • cough
  • loss of appetite
  • diarrhea
  • constipation
  • nausea
  • pancreatitis
  • vomiting
  • abdominal pain
  • oral ulcer
  • abnormal liver function tests
  • hepatitis
  • pruritus
  • erythema
  • rash
  • similar to pemphigus
  • severe and disabling arthralgia
  • rhabdomyolysis
  • elevated lipase
  • increased amylase
  • constipation
  • upper abdominal pain
  • enterocolitis
  • intestinal obstruction
  • gastritis
  • herpes zoster
  • cystitis
  • acute pyelonephritis
  • bronchitis
  • vestibular neuronitis
  • sepsis
  • pneumonia
  • decreased appetite
  • dehydration
  • hyperglycemia
  • cerebral infarction
  • stuttering
  • Alzheimer-type dementia
  • chest pain
  • fever
  • facial edema
  • fatigue
  • chronic obstructive pulmonary disease
  • asthma
  • diabetic foot disease
  • skin lesions
  • liver metastasis
  • acute leukemia
  • basal cell carcinoma
  • non-small cell lung cancer
  • malignant pericardial effusion
  • gastric cancer
  • rectal cancer
  • pancreatic cancer
  • meniscus injury
  • pneumoconiosis
  • congestive heart failure
  • angina pectoris
  • acute myocardial infarction
  • unstable angina
  • cardiac arrest
  • diabetic retinopathy
  • acute kidney injury
  • end-stage renal disease
  • acute cholangitis
  • acute cholecystitis
  • cholangitis
  • dizziness
  • kidney transplant failure
  • anxiety
  • affective disorder
  • insomnia
  • depression
  • contusion
  • bone bruise
  • concussion
  • bone fracture
  • hand fracture
  • palpitations
  • dry eye
  • glaucoma
  • cataract
  • ocular discomfort
  • allergic conjunctivitis
  • polyuria
  • proteinuria
  • stress urinary incontinence
  • hematuria
  • hypotension
  • flushing
  • fatty liver disease
  • cholelithiasis
  • hearing loss
  • erectile dysfunction
  • goiter
  • anemia
  • nausea
  • gastroesophageal reflux disease
  • headache
  • drowsiness
  • chest discomfort
  • weakness
  • pain
  • nosebleed
  • oropharyngeal pain
  • voice disorder
  • allergic rhinitis
  • exertional dyspnea
  • wet cough
  • runny nose
  • pulmonary mass
  • arthralgia
  • osteoporosis
  • arthropathy
  • musculoskeletal discomfort
  • myositis
  • myalgia
  • soft tissue mass
  • postmenopausal osteoporosis
  • rotator cuff syndrome
  • increased serum triglycerides
  • decreased hemoglobin
  • increased serum potassium
  • increased serum creatinine
  • increased serum creatine kinase
  • elevated ALT
  • male pattern hair loss
  • hyperhidrosis
  • hair loss
  • dermatitis
  • anxiety
  • confusional state
  • nocturia
  • dermatitis
  • hypertension

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a closed container to prevent exposure to air or moisture. It is recommended to maintain the storage temperature between 1°C and 30°C.

Appearance and packaging

Appearance

This medication is a bright yellow, oval-shaped extended-release film-coated tablet.

Package unit

30 tablets/bottle, 60 tablets/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.